Cyclin D1–CDK4/6 phosphorylates GTSE1 in cancer cells, preventing its degradation and sustaining high levels across the cell cycle, which enhances proliferation and correlates with poor prognosis.

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 ...

They target specific proteins known as the cyclin-dependent kinases 4 and 6, abbreviated as CDK4/6, which are crucial in cell division and growth. Therefore, they are often referred to as targeted ...

(B) CDK1 and CDK2 bind to multiple cyclins (cyclin types A, B, D and E), whereas CDK4 and CDK6 only partner D-type cyclins. Thick lines represent the preferred pairing for each kinase. (C ...

CDK4/6 inhibitor: from quiescence to senescence ... CSN5 specifically interacts with CDK2 and controls senescence in a cytoplasmic cyclin E-mediated manner. Sci Rep 3: 1054. Akihiro Yoshida, Noriko ...

One major focus of Dr. Diehl’s research concerns the mechanisms whereby growth-signaling pathways regulate the cyclin D/CDK4/6 kinases and from this, the identification of therapeutic vulnerabilities.

A clinical benefit rate of 62.5% was noted among subjects with mutant and wild-type oestrogen receptor 1 (ESR1) disease, all of whom had previously been treated with a cyclin-dependent kinase 4/6 ...

Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors Circle Pharma, a clinical-stage biopharmaceutical company focused on ...

Viruses are the masters of trickery. They mimic, manipulate and usurp cellular functions, but always with an interesting twist. γ-herpesvirus genomes encode an abundance of homologues of cellular ...

an aromatase inhibitor in combination with a CDK4/6 as a front-line therapy for patients ER-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast ...